Ono Pharmaceutical Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
5.7M | +0.04% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Dividend Equity ETF
|
4.7M | +24.54% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
3.6M | +2.38% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
2.6M | +1.22% | |
|
Dimensional ETF Trust-Dimensional International Value ETF
|
1.4M | +9.74% | |
|
J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF
|
1.3M | +0.66% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
215.6K | +4.09% |
Dividend History
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥80 | 0.0% |
| 2024 | ¥80 | +3.9% |
| 2023 | ¥77 | +26.2% |
| 2022 | ¥61 | +20.8% |
| 2021 | ¥51 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥361,361M | ¥447,187M | ¥502,672M | ¥486,871M |
| Gross Profit | ¥267,850M | ¥337,124M | ¥375,547M | ¥338,921M |
| Operating Income | ¥103,196M | ¥141,963M | ¥159,936M | ¥59,748M |
| Pretax Income | ¥105,899M | ¥144,445M | ¥163,963M | ¥64,646M |
| Net Income | ¥80,519M | ¥112,723M | ¥127,977M | ¥50,047M |
| EPS | ¥162.16 | ¥230.79 | ¥266.57 | ¥106.41 |
| Operating Margin | 28.56% | 31.75% | 31.82% | 12.27% |
| Balance Sheet | ||||
| Total Assets | ¥739,203M | ¥882,437M | ¥913,668M | ¥1,064,046M |
| Total Equity | ¥655,906M | ¥741,869M | ¥792,961M | ¥782,451M |
| Total Liabilities | ¥83,297M | ¥140,568M | ¥120,707M | ¥281,595M |
| Cash | ¥69,112M | ¥96,135M | ¥166,141M | ¥204,567M |
| Interest-bearing Debt | ¥8,802M | ¥9,168M | ¥8,862M | ¥146,678M |
| Equity Ratio | 88.73% | 84.07% | 86.79% | 73.54% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥61,829M | ¥159,610M | ¥110,660M | ¥82,459M |
| Investing CF | ¥6,038M | -¥100,259M | ¥48,077M | -¥136,785M |
| Financing CF | -¥60,237M | -¥32,484M | -¥89,848M | ¥94,299M |
| Free CF | ¥49,552M | ¥145,113M | ¥89,831M | ¥74,469M |
| Efficiency | ||||
| ROE | 12.28% | 15.19% | 16.14% | 6.40% |
| ROA | 10.89% | 12.77% | 14.01% | 4.70% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4528
Latest News (5 items)
-
Average Analyst Rating: underperform
Average Target Price: ¥1,709
Rating Score: 3.55 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
